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Abstract. Anosognosia in Alzheimer’s disease (AD) has been associated with greater cognitive impairment and more
behavioural and psychological symptoms of dementia (BPSD). This study examines the incidence, persistence, and remis-
sion rates of anosognosia over a 12-month period, as well as the related risk factors. This was an observational 12-month
prospective study. The longitudinal sample comprised 177 patients with mild or moderate AD, and their respective care-
givers. Anosognosia was assessed using the Anosognosia Questionnaire in Dementia, and we also evaluated cognitive status
(Mini-Mental State Examination), functional disability (Disability Assessment in Dementia), and the presence of BPSD (Neu-
ropsychiatric Inventory). Multinomial logistic regression was used to determine the variables associated with the incidence,
persistence and remission of anosognosia. The prevalence of anosognosia was 39.5% (95% CI = 32.1–47.1) at baseline. At 12
months, incidence was 38.3% (95% CI = 28.6–48.0), persistence was 80.0% (95% CI = 69.9–90.1) and remission was 20.0%
(95% CI = 9.9–30.1). The regression model identified lower age, more education, and the presence of delusions as variables
associated with incidence, and more education, lower instrumental DAD score, and disinhibition as variables associated
with persistence. No variables were associated with remission (n = 14). The presence of anosognosia in AD patients is high.
Education and certain neuropsychiatric symptoms may explain a greater and earlier incidence of anosognosia. However,
anosognosia also increases with greater cognitive impairment and disease severity.
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INTRODUCTION
The lack of insight regarding one’s deficits is com-
monly referred to as anosognosia, which is defined as
a disordered awareness of illness and of its severity
and repercussions [1, 2]. Certain diseases are typ-
ically associated with the denial or minimization
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of the deficits associated with them. For example,
denial of delusions is common among patients with
schizophrenia who have mild cognitive impairment.
A similar phenomenon may be observed in some
neurological disorders. For instance, patients with
hemiplegia following a stroke may deny their inabil-
ity to move the contralateral extremity, while those
with frontotemporal dementia often deny their cogni-
tive impairment, executive dysfunction, and the need
for help and supervision [3–6].
Anosognosia is also common in Alzheimer’s
disease (AD) and is directly linked to cognitive
impairment; consequently, in the later stages of the
disease it becomes indistinguishable from the conse-
quences of impaired cognition [1, 7]. Anosognosic
patients with AD also underestimate their limita-
tions in activities of daily living (ADL), tend not to
adopt compensatory strategies, describe themselves
as they were before the disease onset, and are more
likely to adopt dangerous behaviours [8–10]. In fact,
anosognosia in AD is described as a lack of aware-
ness of impairments in ADL or of neuropsychological
deficits, and it has been associated with the presence
of other behavioural and psychological symptoms of
dementia (BPSD) such as apathy, disinhibition, agita-
tion, irritability, or delusions [11, 12]. Various studies
have also reported an inverse correlation between
anosognosia and depression in dementia, although
some authors have only found this relationship in
cases of mild depression or dysthymia, while oth-
ers describe a stronger association with the apathy
component of depression [13, 14].
Although anosognosia is associated with cogni-
tive impairment, it may also be present in the early
stages of the disease (between 25.7% and 38.5% of
patients with mild dementia present with anosog-
nosia), where it has worse repercussions for both
patients and caregivers [7, 15–17]. Currently, how-
ever, there is no biological marker or gold standard for
detecting anosognosia, and several instruments have
been developed [11, 18, 19]. Furthermore, in the con-
text of AD, anosognosia has been defined in a variety
of ways, not merely in relation to a lack of awareness
of memory impairment but also of behavioural and
functional deficits [18]. In AD, the reported preva-
lence of anosognosia ranges between 3.5% [19] and
more than 50% of cases [20]. The heterogeneity in
the severity of AD patients and the instrument used
to assess anosognosia are two of the main factors
contributing to this variability [1].
There are numerous issues still to be addressed by
research on anosognosia, including the neuropatho-
logical pathways that underlie the phenomenon, the
implications that amnesic syndrome has in implicit
anosognosia, or the impact of executive dysfunc-
tion on the capacity for self-appraisal [21–23].
However, in all patients, whether they suffer from
stroke, schizophrenia, or dementia, the consequences
of anosognosia are similar, namely poor treatment
adherence or denial of the need for treatment, and
increased risk of dangerous behaviours. Importantly,
anosognosia also impacts on quality of life and
implies greater burden on caregivers [17, 19]. Fur-
thermore, the tendency to underestimate symptoms
or to ascribe them to mere aging often delays the
request for a medical consultation or the provision of
well-timed interventions [10].
In the context of research on anosognosia in AD,
there are, to the best of our knowledge, no longitudi-
nal studies that provide data regarding its incidence
and course. Consequently, the aim of the present
study was to identify the factors associated with the
course of anosognosia over a 12-month period in
patients with mild and mild-to-moderate AD.
METHODS
Design and study population
This 12-month prospective observational and
analytic study included a convenience sample of
outpatients seen at one of two memory clinics in
Catalonia (Santa Caterina Hospital in Girona, or Bel-
lvitge University Hospital in Barcelona). They were
all diagnosed with AD according to National Insti-
tute of Neurological and Communicative Disorders
and Stroke-Alzheimer’s Disease and Related Disor-
ders Association criteria [24], scored between 10 and
28 on the Mini-Mental State Exam (MMSE) [25]
and their severity was classified as mild or moderate
severity according to the Global Deterioration Scale
(GDS) [26]. The inclusion criteria included having a
main caregiver, defined as the person who was contin-
uously responsible for helping the patient with ADL.
In order to exclude the presence of anosognosia due
to other medical conditions, the following exclusion
criteria were applied: psychosis, history of neurologi-
cal disorder, vascular or traumatic events, and alcohol
or substance dependency or abuse. Patients were also
excluded if they had severe communication problems
that prevented them from responding adequately to
the assessment measures. The study was approved by
the hospital’s Clinical Research Ethics Committee.
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Procedure
Neurologists from the memory clinics identified
eligible patients according to the inclusion and exclu-
sion criteria and then determined their cognitive
function and GDS stage of dementia [26]. Of the
total number of patients who met the inclusion
criteria, only four families declined to participate.
Recruitment took place between January and Octo-
ber 2011. The assessment protocol lasted 90 min and
was administered by trained psychologists and neu-
rologists, both at baseline and at 12 months. Prior
to the initial assessment interview, the aims of the
study were explained to patients and caregivers, and
informed consent was obtained from all participants.
Instruments
Sociodemographic data (age, gender, education,
marital status, and place of residence) for both
patients and caregivers were collected by means
of a standardized questionnaire. The other aspects
assessed were as follows:
Anosognosia
This was assessed by the Anosognosia
Questionnaire—Dementia (AQ-D), an instru-
ment comprising 30 items, each with four possible
response options (never, sometimes, often, always).
The AQ-D has two forms, one for the patient and one
for the caregiver. The total score is obtained by sub-
tracting the scores on the patient’s form from those
on the caregiver’s form, and ranges between 0 and 90.
A discrepancy of more than 32 points (≥1 standard
deviation) indicates the presence of anosognosia [27].
The AQ-D has high internal consistency (Cronbach’s
alpha = 0.91) and good inter-examiner reliability
(ICC = 0.90). Its factor structure comprises two fac-
tors, a cognitive-functional factor and a behavioural
factor, which explain 38.9% of the total variance [12].
Cognitive function
Cognitive impairment was assessed with the
MMSE. Scores on the MMSE range from 0 to 30, with
a lower score indicating greater cognitive impairment
[25].
Functional status
Specific functional disability was measured using
the Disability Assessment in Dementia (DAD). This
instrument is administered to caregivers and com-
prises 40 dichotomous (yes/no) questions that assess
the ability of the patient to execute 17 basic activities
of daily living (BADL) and 23 instrumental activities
of daily living (IADL) [28].
Behavioural and psychological symptoms of
dementia
The Neuropsychiatric Inventory (NPI) is a vali-
dated method for assessing the presence of BPSD.
It consists of 12 subscales that assess the frequency
and severity of delusions, hallucinations, agita-
tion, depression/dysphoria, anxiety, euphoria, apathy,
disinhibition, irritability, aberrant motor activity,
night-time behavioural disturbances, and appetite
and eating abnormalities. The score is the prod-
uct of the frequency (range = 1–4) and the severity
(range = 1–3) of symptoms, and the total score ranges
from 0 to 144 points [29, 30].
Caregiver burden
Perceived burden was assessed using the Zarit
Burden Interview (ZBI). This is a self-administered
test that consists of 22 Likert-type items. Responses
reflect the caregiver’s perceptions and feelings, and
the total score ranges from 22 to 110 points. Higher
scores indicate greater perceived burden [31].
Severity of dementia
The severity of AD was measured by the GDS,
which ranges from 1 (no cognitive decline) to 7
(severe cognitive decline). A GDS stage 4 corre-
sponds to cases with mild dementia, GDS 5 and GDS
6 to cases with moderate dementia [26].
Statistical analysis
A descriptive analysis of the clinical and sociode-
mographic characteristics of the sample was carried
out, using absolute and relative frequencies for quali-
tative variables and measures of central tendency and
dispersion for quantitative variables. The prevalence
of anosognosia was established using the relative
frequency of each AQ-D group. Changes in anosog-
nosia status groups were determined according to
the presence/absence of anosognosia at baseline and
at follow-up. Specifically, patients without anosog-
nosia at baseline and presence at 12 months were
considered incident cases, those with anosognosia
at baseline but an AQ-D score below 32 at 12
months were considered a remission group, patients
with anosognosia at both baseline and 12 months
were considered persistent cases, and those with-
out anosognosia throughout the study period were
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classified as non-anosognosic patients. The incidence
of anosognosia was established using the relative
frequency of cases with incident anosognosia at
12-month follow-up. Persistence and remission of
anosognosia were established using the AQ-D scores
at baseline and at 12-month follow-up. Only cases
with both baseline and 12-month follow-up data were
considered in the analysis.
Clinical and sociodemographic differences in rela-
tion to the presence, incidence, persistence, or
remission of anosognosia were analysed by means of
parametric and non-parametric tests, in accordance
with criteria of normality. When there was a signif-
icant difference between two measures, Cohen’s (d)
was calculated to determine the effect size.
A multinomial logistic regression model was then
applied to identify the variables that could predict the
incidence, persistence and remission of anosognosia
after 12 months, using sociodemographic and clinical
characteristics as covariables.
Results were expressed as absolute numbers,
percentages, means, standard deviations, and 95%
confidence intervals (CIs). The level of statistical sig-
nificance was set at 0.05 to test hypotheses. All data
processing and analysis was performed using SPSS
v17.0 for Windows.
RESULTS
The baseline sample consisted of 243 patients, of
whom 177 (72.8%) were re-assessed at 12 months.
The reasons for drop-out were increased dementia
severity or comorbidities (42.4%), caregiver-related
problems (e.g., not present at patient’s main resi-
dence, work commitments; 16.7%), death of patient
(9.1%), and other causes (31.8%). The mean age
at baseline of cases which completed the follow-
up was 77.8 years (SD = 6.5); of these, 66.1% were
women and 85.3% lived in their own home. At base-
line, 62.7% of patients (n = 111) were diagnosed with
mild dementia (GDS 4). Regarding caregivers, 46.9%
were the spouse and 48.6% a son or daughter of the
patient. The mean age of caregivers was 61.9 years
(SD = 13.2), and the majority (67.2%) were women.
Anosognosia scores
The mean score on the AQ-D at baseline was 26.7
(SD = 18.3), rising to 32.4 (SD = 18.7) at 12 months
(χ2 = 19.6; df = 1; p = 0.023). In terms of the severity
of dementia, 27.0% of mild cases (GDS 4) presented
anosognosia at baseline (95% CI 18.3–35.7), as com-
pared with 55.2% (95% CI 41.5–58.8) of patients
with moderate dementia. Table 1 shows baseline clin-
ical and sociodemographic characteristics of patients
and caregivers according to the presence or absence
of anosognosia.
There were differences between patients’ and care-
givers’ AQ-D scores, and the change in these scores
over time also differed. Specifically, while patient
perceptions had not changed at 12 months (24.9
at baseline versus 25.5 at 12 months; Z = –0.649;
p = 0.516), caregiver scores increased from 51.6 to
58.0 (Z = –6.5; p < 0.001).
Course of anosognosia over 12 months
The cumulative incidence rate at 12 months was
38.3% (95% CI = 28.6–48.0), the remission rate was
20.0% (95% CI = 9.9–30.1%) and the persistence rate
over 12 months was 80.0% (95% CI = 69.9–90.1).
The incidence among moderate and mild cases was
42.3% and 37.0%, respectively.
Differences in clinical measures were observed
between baseline and the 12-month follow-up. The
mean score on the MMSE fell by 1.6 points (SD = 3.6;
z = –5.4; p < 0.001), while the mean DAD score was
3.4 points lower at 12 months (SD = 9.5; z = –6.0;
p < 0.001). Although the overall score on the NPI did
not change significantly during the follow-up period
(z = 1.2; p = 0.208), a significant difference was
observed on three of its subscales: delusions (z = –2.8;
p = 0.006), apathy (z = –2.3; p = 0.017), and appetite
and eating abnormalities (z = –3.4; p = 0.001). Table 2
shows the baseline characteristics of patients and
caregivers according to the classification of cases
at 12 months. In terms of sociodemographic char-
acteristics, incident cases were significantly younger
than patients with no anosognosia (Cohen’s d = 0.48).
Comparison of the clinical characteristics of the
change in anosognosia status groups (i.e., incidence,
persistence and remission) revealed no significant
differences in their baseline MMSE score (Kruskal-
Wallis = 1.8; df = 2; p = 0.402). However, a trend
was observed across these three groups for func-
tional disability (DAD) and the presence of BPSD
(NPI), with greater functional deterioration being
observed for activities of daily living, both BADL
(Kruskal-Wallis = 18.8; df = 2; p < 0.001) and IADL
(Kruskal-Wallis = 21.5; df = 2; p < 0.001). The com-
parative data recorded at baseline and at 12 month
follow-up, stratified according to incidence, persis-
tence and remission, are presented in Supplementary
Table 1.
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Table 1
Comparison of patient and caregiver clinical and sociodemographic characteristics according to the presence or absence of anosognosia at
baseline
No Anosognosia Anosognosia p d
n = 107 (60.5%) n = 70 (39.5%)
Age of patient, mean (SD) 76.8 (6.7) 79.3 (6.0) 0.016 0.39
Gender of patient (female), n (%) 76 (71.0) 41 (58.6) 0.087 ––
Education, n (%) 0.858 ––
Low 32 (29.9) 22 (31.4)
Elementary 65 (60.7) 40 (57.1)
High 10 (9.3) 8 (11.4)
GDS, n (%) <0.001 0.70
4 81 (73.0) 30 (27.0)
5-6 26 (39.4) 40 (60.6)
MMSE, mean (SD) 19.4 (4.3) 18.4 (5.1) 0.245 ––
NPI, n (%) 13.1 (11.3) 28.1 (20.4) <0.001 0.91
Delusions 0.6 (2.2) 1.1 (2.4) 0.139 ––
Hallucinations 0.2 (1.2) 0.6 (2.0) 0.056 ––
Agitation 1.1 (2.6) 2.4 (3.2) 0.001 0.45
Depression 1.8 (2.5) 2.4 (3.2) 0.214 ––
Anxiety 1.4 (2.4) 1.8 (3.2) 0.790 ––
Euphoria 0.2 (0.9) 0.8 (2.2) <0.001 0.36
Apathy 3.0 (3.8) 5.7 (4.1) <0.001 0.68
Disinhibition 0.3 (0.9) 1.8 (3.1) <0.001 0.66
Irritability 2.0 (3.1) 3.9 (3.8) <0.001 0.55
Aberrant motor disorders 0.5 (1.7) 2.9 (4.1) <0.001 0.76
Sleep disorders 0.5 (1.7) 1.3 (3.1) 0.055 ––
Appetite/Eating 1.3 (2.7) 3.3 (3.9) <0.001 0.60
DAD, mean (SD) 64.3 (9.4) 57.0 (8.7) <0.001 0.81
Age of caregiver, mean (SD) 60.3 (13.4) 64.4 (12.7) 0.054 ––
Gender of caregiver (female), n (%) 66 (61.7) 53 (75.7) 0.052 ––
ZBI, n (%) 34.0 (16.0%) 47.7 (16.7%) <0.001 0.83
GDS, Global Deterioration Scale; MMSE, Mini-Mental State Examination; NPI, Neuropsychiatric Inventory; DAD, Disability Assessment
in Dementia; ZBI, Zarit Burden Interview.
Risk factors associated with the course of
anosognosia
A binary multinomial logistic regression model
was fitted in order to determine the variables asso-
ciated with incidence, persistence, or remission of
anosognosia after 12 months, using absence of
anosognosia as the reference group. The results are
shown in Table 3, and the model has high goodness-
of-fit (Cox & Snell = 0.419; Nagelkerke = 0.524)
and a good likelihood ratio (χ2 = 119.2; df = 15;
p < 0.001). Age, education and delusions were found
to be predictor variables for incident anosognosia,
while education, DAD instrumental score, and dis-
inhibition were associated with the persistence of
anosognosia.
DISCUSSION
The main aims of this study were to determine
cumulative incidence, persistence, and remission
rates of anosognosia at 12 months, and to identify
variables that could predict the course of anosognosia
at baseline.
Although a few studies offer longitudinal data on
the course of anosognosia, their primary aim was not
to study the epidemiology of anosognosia. The lack
of a gold standard for defining and detecting anosog-
nosia has led to several different instruments being
developed to assess it [17, 32, 33], and this makes it
difficult to compare our results with previous studies.
Starkstein et al. also used the AQ-D in a longitu-
dinal study and reported an accumulated incidence
rate much lower than ours (21% versus 38%) [34].
Our higher incidence may be due to the fact that our
sample contains more patients with moderate-severe
and severe dementia, while the sample of Starkstein
et al. included a higher proportion of patients with
mild dementia, and even patients with mild cognitive
impairment. Furthermore, in our study we analysed
probable AD patients, whereas other studies included
mixed dementia patients in the analysis and obtained
certain differences in their results [35].
Incident cases were younger and had a higher
education level than did those cases that remained
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Table 2
Clinical and sociodemographic characteristics of patients and caregivers at baseline, stratified according to the classification of cases at
12 months
Baseline scores
No anosognosia Incidence Persistence Remission
n = 66 (37.3%) n = 41 (23.2%) n = 56 (31.6%) n = 14 (7.9%)
Age of patient*, mean (SD) 78.0 (5.9)a 74.8 (7.4) d 79.6 (6.0) 78.1 (5.8)
Gender of patient (female), n (%) 51 (77.3) 25 (61.0) 33 (58.9) 8 (57.1)
Education, n (%)
Low 25 (37.9) 7 (17.1) 16 (28.6) 6 (42.9)
Elementary 37 (56.1) 28 (68.3) 34 (60.7) 6 (42.9)
High 4 (6.1) 6 (14.6) 6 (10.7) 2 (14.3)
GDS, n (%)
4 51 (77.3) 30 (73.2) 22 (39.3) 8 (57.1)
5-6 15 (22.7) 11 (26.8) 34 (60.7) 6 (42.9)
MMSE, mean (SD) 19.5 (4.3) 19.2 (4.4) 18.6 (5.3) 17.4 (4.1)
NPI*, mean (SD) 12.9 (12.7)b 13.3 (8.7)d 30.4 (21.4) 18.9 (12.4)f
Delusions* 0.3 (1.5)b 1.2 (2.9) 1.4 (2.6) 0.1 (0.3)
Hallucinations 0.2 (1.1)b 0.3 (1.3) 0.8 (2.2) 0.1 (0.3)
Agitation* 1.0 (2.5)b 1.4 (2.5) 2.6 (3.5) 1.5 (2.4)
Depression 1.9 (2.5) 1.5 (2.4) 2.4 (3.2) 2.4 (3.0)
Anxiety 1.7 (2.7) 1.0 (1.8) 2.1 (3.5) 0.8 (1.3)
Euphoria* 0.1 (0.7)b 0.2 (1.3) 1.0 (2.4) 0 (0.0)f
Apathy* 3.0 (3.9)b,c 3.1 (3.6)d 5.7 (4.2)e 5.4 (3.4)
Disinhibition* 0.3 (1.0)b 0.3 (0.9)d 2.1 (3.0) 0.9 (3.2)f
Irritability* 2.0 (3.3)b 2.1 (2.6)d 4.2 (4.0) 2.6 (2.7)
Aberrant motor disorders* 0.5 (1.8)b 0.6 (1.6)d 3.1 (4.2) 1.9 (3.3)
Sleep disorders 0.8 (2.1) 0.2 (0.7)d 1.5 (3.2) 0.8 (2.2)
Appetite/Eating* 1.2 (2.5)b 1.5 (2.8)d 3.5 (4.1)e 2.6 (3.3)
DAD*, mean (SD) 65.1 (9.4)b 63.0 (9.3) 56.1 (8.6) 60.5 (7.8)
Age of caregiver*, mean (SD) 59.3 (13.4)c 61.9 (13.2) 63.4 (13.2) 68.3 (10.4)
Gender of caregiver (female), n (%) 39 (59.1)a 27 (65.9) 43 (76.8) 10 (71.4)
ZBI, mean (SD) 32,3 (17,0)b, 36,8 (14,1)d 50,0 (16,5) 38,8 (15,1)
*Kruskal-Wallis test p < 0.05; aMann-Whitney U test (no anosognosia versus incidence) p < 0.05; bMann-Whitney U test (no anosognosia
versus persistence) p < 0.05. cMann-Whitney U test (no anosognosia versus remission) p < 0.05; dMann-Whitney U test (incidence versus
persistence) p < 0.05; eMann-Whitney U test (incidence versus remission) p < 0.05; f Mann-Whitney U test (persistence versus remission)
p < 0.05. GDS, Global Deterioration Scale; MMSE, Mini-Mental State Examination; NPI, Neuropsychiatric Inventory; DAD, Disability
Assessment in Dementia; ZBI, Zarit Burden Interview.
without anosognosia at 12 months. In addition, inci-
dent cases presented not only a more pronounced
decrease in both cognitive and functional perfor-
mance than did the other cases, but also an increase
in the frequency and severity of BPSD (mainly
delusions). This rapid evolution is characteristic of
patients with higher cognitive reserve [36]. Although
cognitive reserve is usually related with less anosog-
nosia [37, 38], our focus here was on the course of
anosognosia, not simply its presence or absence at
baseline. This means that cases with greater cogni-
tive reserve did not present anosognosia at baseline,
even though their pathophysiology could be represen-
tative of the persistent group. It should also be noted
that incident cases may have an early alteration of the
frontal lobe. A sharp decline in cognitive and func-
tional performance has previously been described in
patients with a high education level and increased
cognitive reserve [39]. In addition, an increased fre-
quency and severity of delusions in young patients
would fit with a frontal pattern, and neuroimaging
studies have already associated anosognosia with a
hypoperfusion of the orbitomedial prefrontal cortex
[40–42], which occurs in cases with frontotemporal
dementia (FTD) too. FTD is usually seen in younger
patients, and anosognosia is one of the clinical criteria
for diagnosis [40].
Severity of dementia is the main determinant
of anosognosia [23], and it was also the factor
that best discriminated between persistent and non-
anosognosia cases in our study. Persistent cases,
which accounted for 80% of cases with anosognosia
at baseline, showed increased disability in IADL
and more frequent and severe BPSD, notably disin-
hibition and apathy. Anosognosia and apathy have
been reported by many studies to show a strong
inter-relationship [12, 19, 34], and Starkstein et al.
concluded that anosognosia is a significant predictor
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Table 3
Forward multinomial logistic regression model for anosognosia status at 12 months
Incidence B OR p 95% CI
Age of patient –0.098 0.907 0.006 0.846 0.972
Education 1.184 3.267 0.003 1.508 7.076
DAD-instrumental –0.072 0.931 0.114 0.851 1.017
BI 0.024 1.024 0.130 0.993 1.055
NPI disinhibition –0.167 0.846 0.454 0.546 1.310
NPI delusions 0.361 1.435 0.015 1.071 1.923
Persistence
Age of patient –0.17 0.983 0.669 0.909 1.063
Education 1.425 4.158 0.002 1.684 10.266
DAD-instrumental –0.290 0.749 < 0.001 0.671 0.835
BI 0.084 1.084 < 0.001 1.050 1.127
NPI disinhibition 0.344 1.410 0.015 1.070 1.859
NPI delusions 0.213 1.237 0.143 0.930 1.645
Remission
Age of patient –0.018 0.983 0.733 0.888 1.087
Education 0.434 1.543 0.443 0.510 4.670
DAD-instrumental –0.163 0.850 0.011 0.750 0.963
ZBI 0.042 1.043 0.043 1.001 1.087
NPI disinhibition 0.199 1.220 0.244 0.873 1.704
NPI delusions –0.596 0.551 0.410 0.133 2.276
B, beta; OR, odds ratio; DAD, Disability Assessment in Dementia; NPI, Neuropsychiatric Inventory; ZBI, Zarit Burden Interview. Reference
category, No anosognosia.
of apathy in AD [34]. Here, we observed an increased
rating of apathy in both persistent and incident
patients, a finding that is consistent with previous
results [34]. Some studies have also demonstrated a
common pathogenesis between anosognosia and apa-
thy, linking the evolution of both [22, 23, 41, 42].
Likewise, several authors have described an inverse
relationship between affective symptoms and anosog-
nosia [13, 14, 19, 20, 43]. Assessing the presence of
anosognosia could therefore help in differentiating
symptoms of depression and apathy and in predicting
apathetic symptoms and greater severity.
Remission of anosognosia was only observed in 14
of our patients. Obviously, this small sample offers
low statistical power in terms of reliability, and incor-
rect baseline classification of these patients cannot
be ruled out. It should also be taken into account
that if anosognosia increases in line with impairment,
the AQ-D may have a floor effect when it comes to
detecting anosognosia in patients with moderate or
moderate-to-severe dementia. These results are con-
sistent with the hypothesis of the “petrified self”
proposed by Mograbi and Morris, who attributed
unawareness to the process of memory impairment
[44]. In this regard, it should be noted that the mean
AQ-D score of our patients remained stable (very
low) over the 12-month period, whereas caregiver
ratings were more negative at follow-up. A further
point to consider is that AQ-D scores are based on
a patient-caregiver discrepancy, and therefore fac-
tors associated with caregiver perceptions should also
be considered. Other authors have pointed out that
instruments based on discrepancies between patients
and caregivers may yield biased results, due to the
effect of caregiver burden and emotional stress [45].
That said, in a previous study we found that caregiver
burden had a minimal effect on the variability of the
AQ-D [46].
Anosognosia is a complex problem that is influ-
enced by factors ranging from the mere anatomical
to the broader psychological and social spheres.
Moreover, the results of the large population-based
study conducted by Mograbi and Morris suggested
that memory impairments or the resulting self-
structure were unlikely to provide a full explanation
for unawareness in AD. Consequently, the authors
concluded that unawareness was associated with dif-
ferent aspects such as depression, dementia severity,
education and socioeconomic level in different cul-
tures [47]. Assessing the course of anosognosia might
reveal this specificity across international regions,
and thus unawareness should be seen not only as
a common neurobiological feature of dementia, one
that increases with severity of dementia, but also as a
phenomenon influenced by social and cultural factors
[48]. In this regard, it would be interesting to develop
new instruments that could account for most of this
variability.
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The main limitations of the present study are those
common to all research on anosognosia and relate
to the intrinsic limitations of the instrument used to
assess anosognosia and the lack of an operational
definition of the phenomenon. As we noted earlier,
anosognosia may be interpreted in various ways, as
affecting cognitive, functional, and/or behavioural
aspects of the patient, and this variation is likely to
influence the results of its assessment [1, 18, 30].
Other specific limitations related to our study sample
should also be taken into account when interpreting
the results obtained. The sample comprised patients
seen consecutively at our neurology department,
whether for the purposes of diagnosis, symptom man-
agement, or a routine visit, and all those included
were community dwellers. It is possible, therefore,
that different results would have been obtained had
we included patients living in residential care. It
should also be noted that our sample includes mod-
erate patients and eight moderate-to-severe cases,
which increased the number of anosognosia patients
across the study period. However, the degenera-
tive process may make it impossible to distinguish
anosognosia from cognitive impairment, and the AQ-
D might not be specific enough with these kinds
of patients. The education level of our sample was
also low, which has an effect on cognitive reserve
and may prevent some comparisons with other
studies.
Finally, almost two of every five patients in
our sample presented with anosognosia at baseline.
Younger age, higher education level, and the presence
of delusions were the main predictors for incident
anosognosia, while higher education level, worse
IADL, and disinhibition were associated with per-
sistence. These data provide a platform for future
research, since the presence of anosognosia is a factor
to consider in new treatment studies using perceived
quality of life and self-related pain as the depen-
dent variable. The number of remitted cases in our
study was small and prevents us from drawing firm
conclusions, and this is another important issue that
requires further research. The importance for clini-
cians of assessing anosognosia is that it could help to
differentiate depressive and apathetic symptoms and
to predict greater severity. For instance, anosognosia
assessment could help to avoid not only a lack of treat-
ment adherence but also risky behaviours related to
driving or financial management [10]. These results
are also relevant to the needs of caregivers of patients
with AD, since anosognosia is known to be one of
the key factors leading to greater burden.
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